ArticleAnnals of surgical treatment and research2026
Safety and efficacy of HLBLS-200 (BleeFix) as a novel hemostatic agent in hepatic surgery: a multicenter, randomized, active-controlled clinical trial.
Article in Annals of surgical treatment and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the safety and efficacy of HLBLS-200 (BleeFix, HLB Cell Co., Ltd.) in patients requiring hemostasis for exudative bleeding following primary hemostasis during hepatic resection. Methods: This prospective, randomized controlled clinical trial was conducted at three hospitals in South Korea, with Arista AH (Becton Dickinson) serving as the active comparator. A total of 156 patients who underwent elective liver resection with exudative bleeding were randomized. The primary endpoint was the hemostasis success rate within 5 minutes of application. Secondary endpoint included hemostatic success rates at 3, 4, 7, and 10 minutes. Safety was assessed by monitoring adverse events over a 12-week follow-up period. Results: The hemostatic success rate within 5 minutes was 98.5% (66/67) in the BleeFix group and 97.0% (65/67) in the control group. The between-group difference was 1.49% (95% confidence interval [CI], -5.72% to 9.07%). The lower bound of the CI (-5.72%) exceeded the predefined non-inferiority margin of -15.00%, confirming the non-inferiority of BleeFix. Treatment-emergent adverse events (TEAEs) were more frequent in the BleeFix group (97.44% Conclusion: BleeFix demonstrated non-inferior hemostatic efficacy compared with Arista AH during hepatectomy. These findings support the clinical use of BleeFix as a safe and effective hemostatic agent for managing exudative bleeding during hepatic resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.